Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctioncytoskeleton-nuclear membrane anchor activity

SYNE3 SYNE2

2.66e-0451042GO:0140444
GeneOntologyMolecularFunctionsmall GTPase binding

KNTC1 DMXL2 PLEKHG2 ASB14 PLEKHG1 ARHGEF7 SYTL5 GOLGA4

2.76e-043211048GO:0031267
GeneOntologyMolecularFunctionbitter taste receptor activity

TAS2R33 TAS2R36 TAS2R19

3.67e-04271043GO:0033038
GeneOntologyMolecularFunctionGTPase binding

KNTC1 DMXL2 PLEKHG2 ASB14 PLEKHG1 ARHGEF7 SYTL5 GOLGA4

5.91e-043601048GO:0051020
GeneOntologyMolecularFunctiontaste receptor activity

TAS2R33 TAS2R36 TAS2R19

6.68e-04331043GO:0008527
DomainKASH

SYNE3 SYNE2

1.66e-044992PF10541
DomainKASH

SYNE3 SYNE2

1.66e-044992IPR012315
DomainKASH

SYNE3 SYNE2

1.66e-044992PS51049
DomainKASH

SYNE3 SYNE2

1.66e-044992SM01249
DomainDEATH-like_dom

CARD16 TNFRSF11B MADD NOD1 NLRP5

1.82e-0499995IPR011029
DomainSpectrin

TRIO SYNE3 SYNE2

2.37e-0423993PF00435
DomainDH_1

TRIO PLEKHG2 PLEKHG1 ARHGEF7

3.48e-0463994PS00741
DomainRhoGEF

TRIO PLEKHG2 PLEKHG1 ARHGEF7

4.66e-0468994SM00325
DomainSpectrin_repeat

TRIO SYNE3 SYNE2

4.78e-0429993IPR002017
DomainRhoGEF

TRIO PLEKHG2 PLEKHG1 ARHGEF7

5.21e-0470994PF00621
DomainDH_2

TRIO PLEKHG2 PLEKHG1 ARHGEF7

5.21e-0470994PS50010
DomainDH-domain

TRIO PLEKHG2 PLEKHG1 ARHGEF7

5.50e-0471994IPR000219
Domain-

TRIO PLEKHG2 PLEKHG1 ARHGEF7

5.50e-04719941.20.900.10
DomainSpectrin/alpha-actinin

TRIO SYNE3 SYNE2

6.41e-0432993IPR018159
DomainSPEC

TRIO SYNE3 SYNE2

6.41e-0432993SM00150
Pubmed

A central chaperone-like role for 14-3-3 proteins in human cells.

CUL4A ERBB2 KRT78 TRIO PLEKHG2 MADD STIM1 PLEKHG1 USP8 SYNE2 SSX2IP MORC3 GOLGA4 GOLGB1

4.23e-078611071436931259
Pubmed

C5orf51 is a component of the MON1-CCZ1 complex and controls RAB7A localization and stability during mitophagy.

DMXL2 SNX17 TOM1 MADD STIM1 NBAS SYNE2 STEAP3 GOLGA4 GOLGB1

3.74e-065041071034432599
Pubmed

The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer.

CUL4A KRT78 TRIO RPS6KA1 XRCC5 STIM1 ARHGEF7 GOLGA4

4.14e-06298107830737378
Pubmed

Polymorphism of Tcrb and Tcrg genes in Biozzi mice: segregation analysis of a new Tcrg haplotype with antibody responsiveness.

TRGC1 TRGC2

9.38e-06210721973682
Pubmed

T cell-specific gamma genes in C57BL/10 mice. Sequence and expression of new constant and variable region genes.

TRGC1 TRGC2

9.38e-06210723486244
Pubmed

Developmentally ordered V-J recombination in mouse T cell receptor gamma locus is not perturbed by targeted deletion of the Vgamma4 gene.

TRGC1 TRGC2

9.38e-06210729126983
Pubmed

Positive regulation of ataxia-telangiectasia-mutated protein (ATM) by E2F transcription Factor 1 (E2F-1) in cisplatin-resistant nasopharyngeal carcinoma cells.

E2F1 ATM

9.38e-062107235303867
Pubmed

Limited diversity of the rearranged T-cell gamma gene.

TRGC1 TRGC2

9.38e-06210723871915
Pubmed

Mapping genomic organization by field inversion and two-dimensional gel electrophoresis: application to the murine T-cell receptor gamma gene family.

TRGC1 TRGC2

9.38e-06210723375073
Pubmed

Structure, organization, and somatic rearrangement of T cell gamma genes.

TRGC1 TRGC2

9.38e-06210723917858
Pubmed

Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer.

ERBB2 E2F1

9.38e-062107229845287
Pubmed

Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.

ERBB2 CD276

9.38e-062107235777267
Pubmed

Organization of the murine T-cell receptor gamma locus.

TRGC1 TRGC2

9.38e-06210728244371
Pubmed

The genomic arrangement of T cell receptor variable genes is a determinant of the developmental rearrangement pattern.

TRGC1 TRGC2

9.38e-062107214691262
Pubmed

ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction.

ERBB2 E2F1

9.38e-062107225246633
Pubmed

Interaction between HER2 and ATM predicts poor survival in bladder cancer patients.

ERBB2 ATM

9.38e-062107236056635
Pubmed

Allelic differences in TCR gamma-chains alter gamma delta T cell antigen reactivity.

TRGC1 TRGC2

9.38e-06210728046225
Pubmed

Transfer-RNA-mediated enhancement of ribosomal proteins S6 kinases signaling for cell proliferation.

ERBB2 RPS6KA1

9.38e-062107228816616
Pubmed

Physical linkage of mouse Tcrg-V genes. II. Regulatory features of the Vg4-Vg3 intergenic region.

TRGC1 TRGC2

9.38e-06210728119740
Pubmed

Developmental cell death in the liver and newborn lethality of Ku86 deficient mice suppressed by antioxidant N-acetyl-cysteine.

XRCC5 ATM

9.38e-062107216916625
Pubmed

New T-cell receptor gamma haplotypes in wild mice and evidence for limited Tcrg-V gene polymorphism.

TRGC1 TRGC2

9.38e-06210728420824
Pubmed

Conservation of Tcrg-V5 and limited allelic sequence polymorphism of the other Tcrg-V genes used by mouse tissue-specific gd-T lymphocytes.

TRGC1 TRGC2

9.38e-06210728550103
Pubmed

Comprehensive interactome profiling of the human Hsp70 network highlights functional differentiation of J domains.

PMS1 DMXL2 DTNA PSMD13 XRCC5 STIM1 PLEKHG1 NBAS SPCS3 SYNE3 SYNE2 SSX2IP STEAP3 ATM GOLGA4 GOLGB1

1.27e-0514871071633957083
Pubmed

Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.

CUL4A USP18 ERBB2 DMXL2 UBE2Q1 RPS6KA1 WDR5 ARIH2 CAPN5 TAF5 DNAH11

1.61e-057301071134857952
Pubmed

Neuregulin/ErbB regulate neuromuscular junction development by phosphorylation of α-dystrobrevin.

ERBB2 DTNA

2.81e-053107222184199
Pubmed

Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.

ERBB2 E2F1

2.81e-053107230684846
Pubmed

Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk.

ERBB2 ATM

2.81e-053107217164260
Pubmed

Polymorphisms in three genes are associated with hemorrhagic stroke.

TNFRSF11B GOLGB1

2.81e-053107226664786
Pubmed

Failed clearance of aneuploid embryonic neural progenitor cells leads to excess aneuploidy in the Atm-deficient but not the Trp53-deficient adult cerebral cortex.

XRCC5 ATM

2.81e-053107215371510
Pubmed

The LINC-anchored actin cap connects the extracellular milieu to the nucleus for ultrafast mechanotransduction.

SYNE3 SYNE2

2.81e-053107223336069
Pubmed

Genetic polymorphism and exon changes of the constant regions of the human T-cell rearranging gene gamma.

TRGC1 TRGC2

2.81e-05310722879283
Pubmed

HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes.

ERBB2 E2F1

2.81e-053107226833126
Pubmed

The PIM-2 kinase is an essential component of the ultraviolet damage response that acts upstream to E2F-1 and ATM.

E2F1 ATM

2.81e-053107223760264
Pubmed

ATM is required for efficient recombination between immunoglobulin switch regions.

XRCC5 ATM

2.81e-053107215520243
Pubmed

[Potentials of DNA-PKcs, Ku80, and ATM in enhancing radiosensitivity of cervical carcinoma cells].

XRCC5 ATM

2.81e-053107217626748
Pubmed

Langerhans cells are not required for epidermal Vgamma3 T cell homeostasis and function.

TRGC1 TRGC2

2.81e-053107221486908
Pubmed

Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.

ERBB2 ATM

2.81e-053107217132159
Pubmed

ATM antagonizes NHEJ proteins assembly and DNA-ends synapsis at single-ended DNA double strand breaks.

XRCC5 ATM

2.81e-053107232890395
Pubmed

Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.

PMS1 NRDE2 DMXL2 CEP85 RPS6KA1 FBRSL1 SRP72 MADD ARHGEF7 AP4B1

3.35e-056501071038777146
Pubmed

Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis.

ERBB2 DMXL2 UBE2Q1 TRIO TOM1 MADD STIM1 SYNE3 SSX2IP DNAH11

5.46e-056891071036543142
Pubmed

Wortmannin potentiates integrase-mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses.

XRCC5 ATM

5.60e-054107211158303
Pubmed

Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.

ERBB2 XRCC5

5.60e-054107219906305
Pubmed

Kinetochore protein MAD1 participates in the DNA damage response through ataxia-telangiectasia mutated kinase-mediated phosphorylation and enhanced interaction with KU80.

XRCC5 ATM

5.60e-054107232944396
Pubmed

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.

E2F1 ATM

5.60e-054107226928463
Pubmed

HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors.

ERBB2 E2F1

5.60e-054107224362522
Pubmed

E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis.

E2F1 ATM

5.60e-054107215140942
Pubmed

Regulation of human polλ by ATM-mediated phosphorylation during non-homologous end joining.

XRCC5 ATM

5.60e-054107228109743
Pubmed

Oncogenes and the DNA damage response: Myc and E2F1 engage the ATM signaling pathway to activate p53 and induce apoptosis.

E2F1 ATM

5.60e-054107216582589
Pubmed

Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2.

E2F1 ATM

5.60e-054107215024084
Pubmed

Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation.

E2F1 ATM

5.60e-054107211459832
Pubmed

Mapping the H(+) (V)-ATPase interactome: identification of proteins involved in trafficking, folding, assembly and phosphorylation.

ATP6V1C1 DMXL2 ARHGEF7

7.85e-0527107326442671
Pubmed

BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery.

XRCC5 ATM

9.32e-055107220668194
Pubmed

Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.

ERBB2 ATM

9.32e-055107220177704
Pubmed

ATM-mediated stabilization of hMutL DNA mismatch repair proteins augments p53 activation during DNA damage.

PMS1 ATM

9.32e-055107215226443
Pubmed

Molecular characterization of ubiquitin-specific protease 18 reveals substrate specificity for interferon-stimulated gene 15.

USP18 USP8

9.32e-055107224533902
Pubmed

Crbn modulates calcium influx by regulating Orai1 during efferocytosis.

CUL4A STIM1

9.32e-055107233127885
Pubmed

Selective roles of E2Fs for ErbB2- and Myc-mediated mammary tumorigenesis.

ERBB2 E2F1

9.32e-055107224276244
Pubmed

RAG2 and XLF/Cernunnos interplay reveals a novel role for the RAG complex in DNA repair.

XRCC5 ATM

9.32e-055107226833222
Pubmed

Structure of a gammadelta T cell receptor in complex with the nonclassical MHC T22.

TRGC1 TRGC2

9.32e-055107215821084
Pubmed

Genetic interactions between ATM and the nonhomologous end-joining factors in genomic stability and development.

XRCC5 ATM

9.32e-055107211248063
Pubmed

Structural requirements for the assembly of LINC complexes and their function in cellular mechanical stiffness.

SYNE3 SYNE2

9.32e-055107218396275
Pubmed

Structural analysis of the RZZ complex reveals common ancestry with multisubunit vesicle tethering machinery.

KNTC1 NBAS

9.32e-055107220462495
Pubmed

Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.

PMS1 CEP85 TRIO DTNA SNX17 RNF213 PSMD13 MADD STIM1 SYNE2 SSX2IP GOLGA4

9.51e-0510491071227880917
Pubmed

Role of the translationally controlled tumor protein in DNA damage sensing and repair.

XRCC5 ATM

1.40e-046107222451927
Pubmed

T cell receptor signaling for γδT cell development.

TRGC1 TRGC2

1.40e-046107230976362
Pubmed

Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu.

ERBB2 RPS6KA1

1.40e-046107212917345
Pubmed

BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8.

PARP9 ATM

1.40e-046107223230272
Pubmed

Structural Analysis of Different LINC Complexes Reveals Distinct Binding Modes.

SYNE3 SYNE2

1.40e-046107233058875
Pubmed

TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton.

SYNE3 SYNE2

1.40e-046107218827015
Pubmed

DNA-PK suppresses a p53-independent apoptotic response to DNA damage.

XRCC5 ATM

1.40e-046107219057578
Pubmed

Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.

E2F1 ATM

1.40e-046107230733337
Pubmed

Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans.

ERBB2 E2F1

1.40e-046107233497358
Pubmed

Proteomic Analysis Reveals a Role for RSK in p120-catenin Phosphorylation and Melanoma Cell-Cell Adhesion.

DTNA RPS6KA1 STEAP3 MORC3 AP4B1

1.41e-04160107531678930
Pubmed

A protein interaction landscape of breast cancer.

PMS1 ERBB2 TRIO ACO1 TOM1 E2F1 XRCC5 SMARCD1 TRMT1L

1.54e-04634107934591612
Pubmed

Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women.

PMS1 ERBB2 E2F1 XRCC5 ATM

1.87e-04170107519064572
Pubmed

Stoichiometry of the murine gammadelta T cell receptor.

TRGC1 TRGC2

1.95e-047107216418397
Pubmed

Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk.

TRGC1 TRGC2

1.95e-04710727477352
Pubmed

Synthetic lethality between PAXX and XLF in mammalian development.

XRCC5 ATM

1.95e-047107227798842
Pubmed

Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3.

RPS6KA1 ATM

1.95e-047107212562765
Pubmed

Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during nonhomologous end-joining.

XRCC5 ATM

1.95e-047107225818648
Pubmed

Centrosomal localization of DNA damage checkpoint proteins.

XRCC5 ATM

1.95e-047107217171639
Pubmed

The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion.

STIM1 NBAS SPCS3 SYNE3 STEAP3

2.20e-04176107528692057
Pubmed

Ring finger protein 213 assembles into a sensor for ISGylated proteins with antimicrobial activity.

USP18 TOM1 RNF213 PSMD13

2.26e-0496107434599178
Pubmed

Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis.

TOM1 NMD3 STIM1 PPP2R2C CEP250 GOLGB1

2.60e-04285107632838362
Pubmed

BioID reveals an ATG9A interaction with ATG13-ATG101 in the degradation of p62/SQSTM1-ubiquitin clusters.

DMXL2 SNX17 STEAP3 WDFY3 AP4B1 GOLGA4

2.60e-04285107634369648
Pubmed

Morc3 mutant mice exhibit reduced cortical area and thickness, accompanied by altered haematopoietic stem cells niche and bone cell differentiation.

TNFRSF11B MORC3

3.33e-049107227188231
Pubmed

Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas.

ERBB2 ATM

3.33e-049107220838624
Pubmed

Deregulated E2f-2 underlies cell cycle and maturation defects in retinoblastoma null erythroblasts.

E2F1 ATM

3.33e-049107217923680
Pubmed

Chromatin association of XRCC5/6 in the absence of DNA damage depends on the XPE gene product DDB2.

CUL4A XRCC5

3.33e-049107228035050
Pubmed

Elongation factor 1 alpha1 and genes associated with Usher syndromes are downstream targets of GBX2.

GBX1 USH2A

3.33e-049107223144817
Pubmed

Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions.

XRCC5 ATM

3.33e-049107218579371
Pubmed

A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.

ERBB2 TRIO DTNA STIM1 USP8 STEAP3 GOLGB1

3.34e-04421107736976175
Pubmed

The DNA sequence and analysis of human chromosome 14.

NRDE2 SMOC1 SYNE3 SYNE2

3.94e-04111107412508121
Pubmed

Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90/R2TP chaperones.

CUL4A SRP72 WDR5 PSMD13 XRCC5 GTPBP10 STIM1 USP8 ARHGEF7 SYNE2 TRMT1L GOLGA4 GOLGB1

4.12e-0414151071328515276
Pubmed

LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy.

KNTC1 KRT78 TRIO XRCC5 NBAS

4.14e-04202107533005030
Pubmed

Genes that distinguish physiological and pathological angiogenesis.

PRND CD276

4.15e-0410107217560335
Pubmed

HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.

CUL4A ATM

4.15e-0410107218514189
Pubmed

Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.

ERBB2 ACO1 SNX17 RNF213 EXTL2 USP8 STEAP3 ATM WDFY3 ST8SIA4 GOLGB1

4.35e-0410611071133845483
Pubmed

Human transcription factor protein interaction networks.

CEP85 DTNA FBRSL1 SRP72 E2F1 WDR5 PSMD13 XRCC5 RLF SYNE2 SMARCD1 TRMT1L TAF5

4.52e-0414291071335140242
Pubmed

Voltage-dependent conformational changes of Kv1.3 channels activate cell proliferation.

KRT78 ABCA13 RNF213 GOLGB1 NLRP5

4.73e-04208107533230847
InteractionZER1 interactions

CUL4A TOM1 NT5C3B CAPN5 ATM GOLGA4

5.61e-06881026int:ZER1
InteractionSYNM interactions

CUL4A ERBB2 DTNA STIM1 SYNE3

1.11e-05581025int:SYNM
GeneFamilySpectrin repeat containing nuclear envelope family

SYNE3 SYNE2

7.84e-0546621252
GeneFamilyPleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing

TRIO PLEKHG2 PLEKHG1 ARHGEF7

9.85e-0566664722
GeneFamilyTaste 2 receptors

TAS2R33 TAS2R36 TAS2R19

3.87e-04396631162
GeneFamilyWD repeat domain containing

DMXL2 WDR5 PPP2R2C WDFY3 TAF5

2.68e-03262665362
GeneFamilyT cell receptor gamma locus at 7p14

TRGC1 TRGC2

2.89e-0322662375
GeneFamilyNLR family

NOD1 NLRP5

3.73e-0325662666
CoexpressionGSE21546_UNSTIM_VS_ANTI_CD3_STIM_SAP1A_KO_AND_ELK1_KO_DP_THYMOCYTES_UP

USP18 KRT78 RNF213 TNFRSF11B TDRD7 PHF11 PARP9

1.07e-051891047M7539
CoexpressionGSE2706_UNSTIM_VS_8H_R848_DC_DN

USP18 SESN3 RNF213 OAS2 TNFRSF11B TDRD7 PARP9

1.40e-051971047M4694
CoexpressionGSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_6H_DN

USP18 RNF213 OAS2 RLF PHF11 PARP9 MORC3

1.44e-051981047M4264
CoexpressionGSE30083_SP1_VS_SP4_THYMOCYTE_DN

RNF213 OAS2 MADD TDRD7 KLHDC1 NOD1 SYNE2

1.54e-052001047M5030
CoexpressionDAUER_STAT3_TARGETS_DN

USP18 OAS2 TDRD7 ST8SIA4

3.98e-05481044M13696
CoexpressionZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_UP

USP18 ATP6V1C1 DMXL2 AOAH TBC1D2 RNF213 OAS2 CARD16 TDRD7 NOD1 PHF11 PARP9 WDFY3 ST8SIA4

4.69e-05101210414M40868
CoexpressionGSE6259_FLT3L_INDUCED_DEC205_POS_DC_VS_CD8_TCELL_DN

AOAH RNF213 OAS2 TDRD7 NOD1 PHF11

6.96e-051741046M6769
CoexpressionWANG_RESPONSE_TO_FORSKOLIN_UP

TRGC1 SPCS3 MED28

1.01e-04231043M14942
CoexpressionGSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_4H_DN

USP18 RNF213 OAS2 RLF PHF11 PARP9

1.10e-041891046M4261
CoexpressionXIE_ST_HSC_S1PR3_OE_UP

USP18 RNF213 OAS2 TDRD7 PARP9 CD276

1.10e-041891046M41755
CoexpressionGSE21546_UNSTIM_VS_ANTI_CD3_STIM_ELK1_KO_DP_THYMOCYTES_UP

USP18 RNF213 TDRD7 NOD1 PHF11 PARP9

1.13e-041901046M7537
CoexpressionERWIN_COHEN_BLOOD_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_UP

USP18 RNF213 OAS2 TDRD7 PARP9

1.14e-041191045M41139
CoexpressionGSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_8H_DN

USP18 RNF213 OAS2 GBX1 PHF11 PARP9

1.34e-041961046M4267
CoexpressionGSE18791_UNSTIM_VS_NEWCATSLE_VIRUS_DC_10H_DN

USP18 OAS2 CARD16 EXTL2 PHF11 PARP9

1.38e-041971046M4294
CoexpressionGSE21546_ELK1_KO_VS_SAP1A_KO_AND_ELK1_KO_DP_THYMOCYTES_UP

USP18 RNF213 TDRD7 PHF11 PARP9 ATM

1.38e-041971046M7545
CoexpressionGSE21546_WT_VS_SAP1A_KO_DP_THYMOCYTES_UP

USP18 RNF213 OAS2 TDRD7 PHF11 PARP9

1.38e-041971046M7543
CoexpressionGSE13485_DAY3_VS_DAY7_YF17D_VACCINE_PBMC_DN

USP18 RNF213 OAS2 TDRD7 PHF11 PARP9

1.41e-041981046M3302
CoexpressionGSE360_L_DONOVANI_VS_T_GONDII_MAC_UP

ERBB2 TRIO AOAH FABP3 WDFY3 USH2A

1.45e-041991046M5233
CoexpressionGSE21927_SPLEEN_C57BL6_VS_4T1_TUMOR_BALBC_MONOCYTES_DN

USP18 UBE2Q1 OAS2 TDRD7 PHF11 MORC3

1.49e-042001046M7595
CoexpressionGSE13485_CTRL_VS_DAY7_YF17D_VACCINE_PBMC_DN

USP18 RNF213 OAS2 TDRD7 PHF11 PARP9

1.49e-042001046M3288
CoexpressionGSE30083_SP1_VS_SP3_THYMOCYTE_DN

USP18 RNF213 OAS2 AXDND1 KLHDC1 SYNE2

1.49e-042001046M5026
CoexpressionHALLMARK_INTERFERON_GAMMA_RESPONSE

USP18 RNF213 OAS2 TDRD7 NOD1 ST8SIA4

1.49e-042001046M5913
CoexpressionGSE5455_EX_VIVO_VS_POST_24H_INCUBATION_MONOCYTES_FROM_TUMOR_BEARING_MOUSE_DN

USP18 RPS6KA1 ICAM2 RNF213 OAS2 KLHDC1

1.49e-042001046M6580
CoexpressionGSE38681_WT_VS_LYL1_KO_LYMPHOID_PRIMED_MULTIPOTENT_PROGENITOR_DN

USP18 OAS2 TDRD7 SYNE2 PARP9 MORC3

1.49e-042001046M9020
CoexpressionGSE34006_WT_VS_A2AR_KO_TREG_DN

USP18 OAS2 TDRD7 SYNE2 PARP9 MORC3

1.49e-042001046M9042
CoexpressionGSE36527_CD69_NEG_VS_POS_TREG_CD62L_LOS_KLRG1_NEG_UP

USP18 OAS2 TDRD7 SYNE2 PARP9 MORC3

1.49e-042001046M9030
CoexpressionGSE34006_A2AR_KO_VS_A2AR_AGONIST_TREATED_TREG_UP

USP18 SESN3 OAS2 TDRD7 PARP9 MORC3

1.49e-042001046M9051
CoexpressionGSE26030_TH1_VS_TH17_DAY5_POST_POLARIZATION_UP

USP18 RNF213 OAS2 TDRD7 PARP9 CAPN5

1.49e-042001046M8564
CoexpressionGSE2770_TGFB_AND_IL4_VS_IL12_TREATED_ACT_CD4_TCELL_6H_UP

USP18 RNF213 PLEKHG2 GPR162 MADD PARP9

1.49e-042001046M6096
CoexpressionERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_7DY_UP

USP18 RNF213 OAS2 PARP9

1.96e-04721044M41023
CoexpressionWANG_RESPONSE_TO_ANDROGEN_UP

TRGC1 SPCS3 MED28

2.06e-04291043M16075
CoexpressionSANA_RESPONSE_TO_IFNG_UP

RNF213 OAS2 PARP9 ST8SIA4

2.41e-04761044M4551
CoexpressionRODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP

PMS1 KNTC1 ATP6V1C1 GTPBP10 FAM200B NMD3 SPCS3 SSX2IP STEAP3 FAM216A

2.46e-0464410410M10501
CoexpressionBOSCO_INTERFERON_INDUCED_ANTIVIRAL_MODULE

OAS2 TDRD7 NOD1 GOLGA4

2.66e-04781044M2532
CoexpressionAtlasdev gonad_e13.5_M_GermCell_Oct_top-relative-expression-ranked_1000

PMS1 KNTC1 ATP6V1C1 DMXL2 CEP85 RNF213 WDR5 SMOC1 XRCC5 TDRD7 PHF11 SYT14 ATM MORC3 TAF5

5.72e-0681010015gudmap_dev gonad_e13.5_M_GermCell_Oct_1000
CoexpressionAtlaskidney_adult_GlomCapSys_Tie2_k-means-cluster#3_top-relative-expression-ranked_200

ICAM2 GVINP1 PHF11 ST8SIA4

3.36e-05391004gudmap_kidney_adult_GlomCapSys_Tie2_k3_200
ToppCellT_cells-ISG-high_CD4+_T_cells|World / Immune cells in Kidney/Urine in Lupus Nephritis

USP18 RNF213 OAS2 TDRD7 NOD1 SYNE2 PHF11 PARP9

1.58e-0818810586f8946d4710f6e32c937213f99b790b098b8819c
ToppCellMild-CD4+_T_activated|World / Disease group and Cell class

USP18 ICAM2 OAS2 CARD16 TDRD7 PHF11 PARP9 MORC3

2.18e-081961058417b4fc2e4388f34c410576131b02936f93e46b6
ToppCellVE-CD4-antiviral_CD4|VE / Condition, Cell_class and T cell subcluster

USP18 ICAM2 RNF213 OAS2 CARD16 SYNE2 PHF11 PARP9

2.46e-081991058056a0538ca5e825ae6195b4c76c208708a014533
ToppCellmild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

USP18 RNF213 OAS2 SYNE2 PARP9 ATM GOLGA4 GOLGB1

2.55e-08200105812f1685ce8f218433068e090c9d839cd5a1910bf
ToppCellT_cells-ISG-high_CD4+_T_cells|T_cells / Immune cells in Kidney/Urine in Lupus Nephritis

USP18 RNF213 OAS2 TDRD7 NOD1 PHF11 PARP9

2.30e-071791057af35ef8a7768cee0c2af0590e5bec35cee6a4714
ToppCellsaliva-Severe-critical_progression_d28-40-Myeloid-Macrophage-macrophage,_alveolar-Macro_c2-CCL3L1|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

USP18 DMXL2 RNF213 OAS2 CARD16 PHF11 PARP9

2.87e-071851057f30fb9d75cdb757b206312992aaf7485bc900f96
ToppCellCOVID-19_Moderate-NK_activated|World / disease group, cell group and cell class

USP18 ERBB2 TRGC1 TRGC2 OAS2 SYNE2 PARP9

2.98e-071861057ff8f32f69516bf785224fa12f8139a95359b0279
ToppCell3'_v3-bone_marrow-Lymphocytic_NK-NK_CD16|bone_marrow / Manually curated celltypes from each tissue

TRGC1 ICAM2 AOAH RNF213 CARD16 SYNE2 ATM

3.96e-0719410577773501e076d470158dbc1d7f10c67152b326eb7
ToppCellB_cells-ISG-high_B_cells|B_cells / Immune cells in Kidney/Urine in Lupus Nephritis

USP18 RNF213 OAS2 CARD16 TDRD7 PHF11 PARP9

4.10e-071951057b64d9e1a8834401b4dc501566546647754ae21fc
ToppCellCOVID-19_Moderate-CD8+_T_activated|COVID-19_Moderate / disease group, cell group and cell class

USP18 TRGC2 AOAH RNF213 OAS2 SYNE2 PARP9

4.39e-0719710574711ecb157e907758a5021248ae8b043d17672c6
ToppCellCV-Mild-1|CV / Virus stimulation, Condition and Cluster

USP18 RNF213 OAS2 CARD16 SYNE2 PHF11 PARP9

4.54e-0719810574b078714c49e7befb7b113d72485e712236d35fa
ToppCellPBMC-Severe-cDC_9|Severe / Compartment, Disease Groups and Clusters

USP18 ICAM2 RNF213 OAS2 CARD16 PHF11 PARP9

4.86e-072001057ea3b22126d9dfd158bb3c3e1323b30514d721ded
ToppCellCOVID-19-COVID-19_Mild-Lymphocyte-T/NK-NK_activated|COVID-19_Mild / Disease, condition lineage and cell class

ERBB2 TRGC1 TRGC2 RNF213 OAS2 SYNE2 PARP9

4.86e-0720010572281debd86e5d92e8fe0397aec9ef670800f7471
ToppCellFLU-Healthy-1|Healthy / Virus stimulation, Condition and Cluster

USP18 RNF213 OAS2 CARD16 SYNE2 PARP9

2.14e-06159105697c8e16a7ac10ebba96daee97f9fb1d4a404f23b
ToppCellFLU-Healthy-1|FLU / Virus stimulation, Condition and Cluster

USP18 RNF213 OAS2 CARD16 SYNE2 PARP9

2.14e-061591056fe2a9f79b058e89214256e736f6e266830cdfa28
ToppCell3'_v3-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8|lymph-node_spleen / Manually curated celltypes from each tissue

SESN3 RNF213 SYNE2 ATM ENPEP GOLGB1

3.25e-0617110562e9a20f8980b78325c52065a9c14ab3656267c05
ToppCellsaliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic-Neutrophil-Neu_c4-RSAD2|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

ACO1 RNF213 OAS2 TDRD7 PHF11 PARP9

3.72e-06175105697616bb5c127284aa9e67bc336dfcf29e137164b
ToppCellSevere-CD4+_T_activated|Severe / Disease group and Cell class

USP18 RNF213 OAS2 ASB14 TDRD7 PHF11

3.97e-061771056a08f170f1143fcdd7d0842a54d9b807a4548f8b7
ToppCellBAL-Control-cDC_1|Control / Compartment, Disease Groups and Clusters

USP18 RNF213 OAS2 TDRD7 PHF11 PARP9

3.97e-061771056aa021f6d62e9d740c5ea499faaf875de835a2865
ToppCellSevere-CD4+_T_activated|World / Disease group and Cell class

USP18 RNF213 OAS2 ASB14 TDRD7 PHF11

4.10e-061781056ef6111238703579a34bd6948bd9d4ca6b7e16063
ToppCellCalu_3-infected|Calu_3 / Cell line, Condition and Strain

USP18 TRIO RNF213 OAS2 SYNE2 PARP9

4.81e-0618310568f7f5000645f24f20a8d7700c4df1f8953a1780b
ToppCellCOVID-19_Mild-CD8+_T_activated|COVID-19_Mild / Disease condition and Cell class

USP18 TRGC2 AOAH OAS2 CARD16 PARP9

4.81e-061831056ac1ca5d613fa9888ccc63cb0bdce95aefd02cdd7
ToppCellCalu_3-infected-SARSCoV2|infected / Cell line, Condition and Strain

USP18 RNF213 OAS2 TDRD7 SYNE2 PARP9

6.14e-0619110562da876d26f37a00dbdf1ee79d724306e8b20f304
ToppCellCV-Healthy-1|CV / Virus stimulation, Condition and Cluster

USP18 RNF213 OAS2 CARD16 PHF11 PARP9

6.33e-061921056934d2e6a65121b24b91d386f7940fb9c1a7357ab
ToppCellCV-Healthy-1|Healthy / Virus stimulation, Condition and Cluster

USP18 RNF213 OAS2 CARD16 PHF11 PARP9

6.33e-0619210562a2052b44e8f679ef484f03ba4fb37b0ec841b88
ToppCellPBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c04-COTL1|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)

RPS6KA1 TRGC1 TRGC2 RNF213 FABP3 SYNE2

6.33e-061921056d9e27b8c2fd64e318a399feb5a51283616e1a30c
ToppCellCOVID-19_Moderate-CD8+_T_activated|World / disease group, cell group and cell class

USP18 TRGC2 RNF213 OAS2 SYNE2 PARP9

6.92e-061951056070c5d3bdbd4ea54a579c01c37fb99bcf823982e
ToppCellCV-Moderate-1|Moderate / Virus stimulation, Condition and Cluster

USP18 RNF213 OAS2 CARD16 PHF11 PARP9

7.12e-061961056b50cfcd87c5b67806450cb8b3c6860ab97f6d3b1
ToppCellMild-CD4+_T_activated|Mild / Disease group and Cell class

USP18 ICAM2 OAS2 CARD16 PHF11 PARP9

7.12e-061961056daa1c3322d81e649161e889e1d78451d2d425d09
ToppCellCV-Moderate-1|CV / Virus stimulation, Condition and Cluster

USP18 RNF213 OAS2 CARD16 PHF11 PARP9

7.33e-061971056e3d00d850b4d191f9592ef993c0eaadfe5710b5f
ToppCellCD8+_Memory_T_cell-CV-1|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster

USP18 RNF213 OAS2 CARD16 PHF11 PARP9

7.33e-061971056e59b47bccc781b2117196fe322efa87559c237c6
ToppCellPBMC-Severe-Lymphocyte-T/NK-NK_cell-NK_activated|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TRGC1 AOAH RNF213 OAS2 SYNE2 ATM

7.55e-0619810560e918e9db9b884f5328d438e90efe065e27266ee
ToppCellMild-CD8+_T_activated|Mild / Disease group and Cell class

USP18 RNF213 OAS2 CARD16 PHF11 PARP9

7.55e-061981056ceac1b51bacfd0dd7fe7c6a666f7927055e1f380
ToppCellPBMC-Severe-Lymphocyte-T/NK-NK_cell-NK_activated-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TRGC1 AOAH RNF213 OAS2 SYNE2 ATM

7.55e-061981056ce92d5fbc2eac27fb246b044fb1914ab92506275
ToppCellPBMC-Severe-Lymphocyte-T/NK-NK_cell-NK_activated|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)

TRGC1 AOAH RNF213 OAS2 SYNE2 ATM

7.55e-061981056fed823d6e684d113bcc9ff3cd1803bb001aa02fa
ToppCellPBMC-Severe-Lymphocyte-T/NK-NK_cell-NK_activated-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

TRGC1 AOAH RNF213 OAS2 SYNE2 ATM

7.55e-0619810561ef3a6bd681c223eed58300348adfef89df5563c
ToppCell10x_5'_v1-Non-neoplastic-Lymphoid-CD4/CD8-CD4_INF-Z|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

USP18 ICAM2 OAS2 SYNE2 PHF11 PARP9

7.77e-061991056d3f36ede2fade550ec8f21a0448e71e1ff579ee2
ToppCellcontrol-CD163+_Monocytes_(Sample_ID1_d7)|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

USP18 DMXL2 AOAH RNF213 OAS2 PARP9

7.77e-061991056933201d32eda12a89660bdbae9114a95cc428a38
ToppCellCOVID-19_Severe-Lymphoid_T/NK-NK_activated|COVID-19_Severe / Disease group, lineage and cell class

TRGC1 AOAH RNF213 OAS2 SYNE2 ATM

7.77e-061991056edf5f80b4c299e6bf462675f2cd3329d86c923d8
ToppCellCOVID_non-vent-Lymphocytic-ILC|COVID_non-vent / Disease condition, Lineage, Cell class and subclass

ERBB2 TRGC1 TRGC2 RNF213 SYNE2 ATM

7.77e-061991056df4f7d5be099e3e6054f3b812ccf70251664e4c0
ToppCellCOVID-19_Moderate-NK|World / disease group, cell group and cell class

ERBB2 TRGC1 AOAH RNF213 SYNE2 ATM

7.77e-061991056c41b67b760831c7d5e19fabcc932a056dc560f93
ToppCellCOVID_non-vent-Lymphocytic-ILC-NK_cell|COVID_non-vent / Disease condition, Lineage, Cell class and subclass

ERBB2 TRGC1 TRGC2 RNF213 SYNE2 ATM

7.77e-061991056ed35d747f11f6ea6a5cb7061057f0a98d9e0db99
ToppCellCOVID-19_Moderate|World / disease group, cell group and cell class

USP18 TRGC2 RNF213 OAS2 SYNE2 PARP9

7.77e-061991056952fac67588ad5676f5939e3c7f8bac803c27064
ToppCellCOVID-19-COVID-19_Mild-Lymphocyte-T/NK-CD8+_T_activated|COVID-19_Mild / Disease, condition lineage and cell class

USP18 TRGC2 OAS2 SYNE2 PHF11 PARP9

7.99e-0620010567751affe353a5208ffad7a58308c588050e77243
ToppCellVE|World / Condition, Cell_class and T cell subcluster

RNF213 OAS2 SPCS3 SYNE2 PHF11 PARP9

7.99e-0620010568ae7cb81de3ffac5acdf3466d4b516d80cac95d3
ToppCellCOVID-19-COVID-19_Mild-Lymphocyte-T/NK-CD4+_T_activated|COVID-19_Mild / Disease, condition lineage and cell class

USP18 SESN3 RNF213 OAS2 SYNE2 PARP9

7.99e-062001056d9e8a0d047d4403fb7265fde7448e23a7780785c
ToppCellCOVID-19-COVID-19_Severe-Lymphocyte-T/NK-NK_activated|COVID-19_Severe / Disease, condition lineage and cell class

TRGC1 AOAH RNF213 OAS2 SYNE2 ATM

7.99e-0620010566a77f9643646bafc1157bf1fc1e4c614860ee642
ToppCellCOVID-19|World / Disease, condition lineage and cell class

RNF213 OAS2 SPCS3 SYNE2 GOLGA4 GOLGB1

7.99e-0620010567dec470c379cd89f05a0f37c8628b21f136e52f0
ToppCellCOVID-19_Severe-MAIT|COVID-19_Severe / disease group, cell group and cell class

KLHL10 TRGC1 TRGC2 AXDND1 SYNE2

2.84e-051501055923ea7ecc0aa05fb0396082cd9c3d1594135f1e0
ToppCellMS-CD4-antiviral_CD4|MS / Condition, Cell_class and T cell subcluster

USP18 RNF213 OAS2 SYNE2 PARP9

3.03e-051521055b1eba2d5a6da3eeb83d40a92976e3e8751ed18ee
ToppCellPBMC-Control-cDC_1|Control / Compartment, Disease Groups and Clusters

USP18 RNF213 OAS2 PHF11 PARP9

3.43e-0515610559b6c5bcac516a62bcc1f5be32ffa8c92735ef0bc
ToppCellfacs-Brain_Myeloid-Cerebellum_|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

USP18 AOAH OAS2 GPR162 PHF11

3.99e-0516110555c762609531a7c5505aa5637abf8e0311568d7fd
ToppCellfacs-Brain_Myeloid-Cerebellum_-18m|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

USP18 AOAH OAS2 GPR162 PHF11

3.99e-051611055b14a83ad07a7acb07c766aa862b527698976b6fc
ToppCellfacs-Brain_Myeloid-Cerebellum_-18m-Myeloid|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

USP18 AOAH OAS2 GPR162 PHF11

3.99e-051611055c5d9d47dcedfbb1ac77f4afaf860ae4d9f26fd3f
ToppCellfacs-Brain_Myeloid-Cerebellum_-18m-Myeloid-nan|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

USP18 AOAH OAS2 GPR162 PHF11

3.99e-05161105526c0d876339bfd34d9a43af5b9fb08f50526f2c9
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_ILC|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)

TRGC1 TRGC2 AOAH E2F1 SYNE2

5.46e-05172105586f52f486d67217fc1b8443ab362c975df2974a4
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c01-FCGR3A|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)

TRGC1 TRGC2 AOAH E2F1 SYNE2

5.46e-051721055fb2df8fea6df5947165f13978f1d1006d15b60fd
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_ILC-NK_cell|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)

TRGC1 TRGC2 AOAH E2F1 SYNE2

5.46e-051721055e38ebb216e4ddcd008148fcbaf709b4f3c83706a
ToppCelldroplet-Lung-LUNG-1m-Myeloid-Proliferating_Dendritic|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

E2F1 SMOC1 GPR162 PHF11 DNAH11

5.61e-05173105515af4a0f7516dbf5c93ba66a19aca073ebe30d04
ToppCell10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-T_lymphocytic-mature_NK_T_cell|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

TRGC1 TRGC2 AOAH SYNE2 ATM

5.61e-05173105536a471576a9d2325066bb14c2f2cd89c67b92915
ToppCellRSV-Healthy-1|Healthy / Virus stimulation, Condition and Cluster

USP18 TBC1D2 RNF213 OAS2 PARP9

5.93e-051751055ff3a27f512a3a710ebc863b7b75cce8167d5440b
ToppCellRSV-Healthy-1|RSV / Virus stimulation, Condition and Cluster

USP18 TBC1D2 RNF213 OAS2 PARP9

5.93e-051751055ca52b99b03535a5b3a2751d6981708dc5b255b91
ToppCelltumor_Lung-B_lymphocytes-Plasma_cells|B_lymphocytes / Location, Cell class and cell subclass

ICAM2 PRND SPCS3 PPP2R2C CAPN5

6.09e-051761055683022c3400e951b26c2b49394dfd3cc415276fe
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TRGC1 TRGC2 RNF213 OAS2 SYNE2

6.26e-051771055d3e6c768b88b7906f3c7fdd00ba20842212c14b1
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TRGC1 TRGC2 RNF213 OAS2 SYNE2

6.26e-051771055f8f101c772c043636bedd6b2ec81409b1d2599bf
ToppCellCOVID-19_Mild-Lymphoid_T/NK-NK_activated|COVID-19_Mild / Disease group, lineage and cell class

TRGC1 TRGC2 RNF213 OAS2 SYNE2

6.26e-0517710556978a22fef40c8b455342373abe7593f5ede0fa4
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

TRGC1 TRGC2 RNF213 OAS2 SYNE2

6.26e-051771055936ab2b180a052387124f68d0c7f41c0b164e748
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

TRGC1 TRGC2 RNF213 OAS2 SYNE2

6.26e-051771055d5aeda113afaa2425874394610344570c9078478
ToppCellMS-Treg-naive_CD4|MS / Condition, Cell_class and T cell subcluster

FBRSL1 PLEKHG2 PLEKHG1 MORC3 TAF5

6.77e-0518010557ca083616926d98420fa11a6e5ebc981623f79ac
ToppCellPBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)

USP18 TRGC1 AOAH TBCCD1 SYNE2

6.95e-05181105512ff56fa2949c8d53360cdf2cacfd326e65b54aa
ToppCellfacs-Marrow-B-cells-18m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RPS6KA1 TOM1 GPR162 SYNE2 ST8SIA4

6.95e-051811055e6c78038b14100e0c9c6fe25e8f0b75c02c33549
ToppCell356C-Lymphocytic-NK_cells-NK_cell_B2|356C / Donor, Lineage, Cell class and subclass (all cells)

TRGC1 TRGC2 AOAH SYNE2 ATM

7.14e-05182105552baef8173df0a55307c375674a37c2488066738
ToppCellControl-Endothelial-Endothelial-Activated_Alv_Cap|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ICAM2 RNF213 OAS2 PLEKHG1 PARP9

7.32e-051831055e81c142770f44fd902b0631bc360c5b5339d4c75
ToppCellCV-Moderate-7|Moderate / Virus stimulation, Condition and Cluster

KNTC1 DMXL2 RNF213 NBAS ST8SIA4

7.71e-051851055a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-CD4/CD8-CD8_NK_sig|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

TRGC1 TRGC2 GVINP1 SYNE2 ATM

7.91e-05186105571e87c4c755ab607689cb050f5a363cb520a0f53
ToppCellCiliated_cells-B-IPF_01|World / lung cells shred on cell class, cell subclass, sample id

ABCA13 TSPAN19 ASB14 GPR162 DNAH11

7.91e-051861055f72267d533fd0c5280d9741ceee3dd116300a7e4
ToppCellCOVID-19_Severe-CD8+_T_activated|COVID-19_Severe / Disease condition and Cell class

USP18 TRGC2 OAS2 PHF11 PARP9

7.91e-051861055fc087b79240fe7ada5810d4f4b3c7287eab598ff
ToppCellCV-Moderate-7|CV / Virus stimulation, Condition and Cluster

KNTC1 DMXL2 RNF213 NBAS ST8SIA4

7.91e-0518610558571956890fc9894d766ba294a28e376b4aba428
ToppCellrenal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

ABCA13 TNFRSF11B SYNE2 WDFY3 DNAH11

8.53e-051891055904b8337e2cabac2f0bf5dad5598fc429581ed81
ToppCell3'-GW_trimst-1.5-SmallIntestine-Hematopoietic-T_cells-Activated_T|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

TRGC1 TRGC2 AOAH PPP2R2C TRMT12

8.53e-051891055c38157c8cf5c0c1f560011ef5cc5892a049ee2b7
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

ABCA13 SESN3 TNFRSF11B SYNE2 DNAH11

8.74e-051901055b855b8b7d3439023390ca44629c1a99f5d4c6801
ToppCellCOVID-19-kidney-NK|kidney / Disease (COVID-19 only), tissue and cell type

TRGC1 TRGC2 AOAH ATM ST8SIA4

8.74e-051901055e3ca3c9fb9e27670a5dd128dd6564ff98a57159e
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

ABCA13 SESN3 TNFRSF11B SYNE2 DNAH11

8.74e-051901055a5db902ad112a0c0a0a7f1a2e38718bb3bd11412
ToppCellCD8+_Memory_T_cell-CV-7|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster

KNTC1 RNF213 NBAS SYNE3 ST8SIA4

8.96e-0519110559454f642c3621370fa23640b631301346b300950
ToppCellMild/Remission-B_activate-7|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)

USP18 RNF213 OAS2 PHF11 PARP9

8.96e-051911055382686d62f7b8576c44bb9726a4e10dc26fd348e
ToppCell15-Trachea-Epithelial-Intermediate_ciliated|Trachea / Age, Tissue, Lineage and Cell class

ABCA13 TSPAN19 GPR162 CAPN5 DNAH11

9.18e-0519210559cbe961a800c981cdc742a47ed18e9c8eb6430bd
ToppCell5'-GW_trimst-2-SmallIntestine-Epithelial-goblet|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

TBC1D2 TNFRSF11B TDRD7 SYTL5 CAPN5

9.41e-051931055402aad2f9e789ad1f2e1536cdc9ce61de7625427
ToppCell3'-Pediatric_IBD-SmallIntestine-Hematopoietic-T_cells-CD8_Tmem|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract

TRGC1 TRGC2 AOAH RNF213 ATM

9.41e-05193105553b3f9a8967541ca817a250439a7928d36b45386
ToppCellCOVID-19_Severe-CD8+_T_activated|World / disease group, cell group and cell class

TRGC2 RNF213 SYNE2 PHF11 PARP9

9.41e-051931055ddc1db516568e03be8e82b2ca770c67756418185
ToppCell5'-GW_trimst-2-SmallIntestine-Epithelial-goblet-Goblet_cell|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

TBC1D2 TNFRSF11B TDRD7 SYTL5 CAPN5

9.41e-0519310557ee3b1ef5c455f321b4e154ae62c69543fe9b30e
ToppCell3'_v3-bone_marrow-Lymphocytic_NK|bone_marrow / Manually curated celltypes from each tissue

TRGC1 ICAM2 AOAH RNF213 SYNE2

9.41e-051931055e790ab76c12f74a13936c231076f1e397283efb3
ToppCellIIH-CD8-CD8_1|IIH / Condition, Cell_class and T cell subcluster

TRGC1 TRGC2 AOAH RNF213 SYNE2

9.41e-051931055c5a4926003906d6726155f19061b73fb45d9962c
ToppCell10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-T_lymphocytic-CD8-positive,_alpha-beta_T_cell|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

TRGC1 TRGC2 AOAH SYNE2 ATM

9.41e-051931055a594f89a18273797506287d9e22f72abe53e4920
ToppCellmoderate-Myeloid-Monocyte-derived_Macrophage|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls

USP18 RNF213 OAS2 TNFRSF11B GOLGA4

9.41e-05193105522455801194bd8c73c5c397f5eac4f723429c383
ToppCellMild_COVID-19|World / Disease group,lineage and cell class （2021.01.30）

USP18 DTNA ICAM2 OAS2 PARP9

9.41e-051931055325b0768827bf8701bfb7f686bb11fd8b1a41a5c
ToppCellsystemic_lupus_erythematosus-treated-Lymphocytic_NK-natural_killer_cell|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex

USP18 ERBB2 RNF213 SYNE2 ATM

9.64e-051941055a3a81638b55cb5fc08fe83c8b88f68d49b87e6cb
ToppCell367C-Lymphocytic-CD8+_Cytotoxic_T-cell|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

TRGC1 TRGC2 ICAM2 AOAH SYNE2

9.64e-051941055a8dc3336aa4ef497f6d26cede02ddac425e7c655
ToppCellMild/Remission-B_activate-7|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)

USP18 RNF213 OAS2 PHF11 PARP9

9.64e-05194105501c97543972159a9468272da06e7e611e2c21fae
ToppCellCOVID-19-lung-NK_cells|COVID-19 / Disease (COVID-19 only), tissue and cell type

TRGC1 TRGC2 AOAH SYNE2 ATM

9.64e-0519410554c92f18e0a34fb50630d4b260eaf179202508b6d
ToppCellPBMC-Mild|PBMC / Compartment, Disease Groups and Clusters

USP18 RNF213 OAS2 SPCS3 PARP9

9.64e-051941055d1366b169d14011194e61d16b6b0953349febc78
ComputationalGenes upregulated in subsets of cells of a given type within various tumors

SYNE2 ATM GOLGA4 GOLGB1

1.86e-0449634GAVISH_3CA_METAPROGRAM_CD8_T_CELLS_CHROMATIN
ComputationalGenes upregulated in subsets of cells of a given type within various tumors

USP18 RNF213 OAS2 PARP9

2.02e-0450634GAVISH_3CA_METAPROGRAM_B_CELLS_INTERFERON
ComputationalGenes upregulated in subsets of cells of a given type within various tumors

TRIO SESN3 ARHGEF7 GOLGB1

2.02e-0450634GAVISH_3CA_MALIGNANT_METAPROGRAM_29_NPC_OPC
DrugNifenazone [2139-47-1]; Down 200; 13uM; MCF7; HT_HG-U133A

CEP85 DTNA TBC1D2 STIM1 CEP250 ARIH2 WDFY3 ENPEP

3.21e-0619710382285_DN
Diseasealcohol use disorder (implicated_via_orthology)

ERBB2 FBRSL1 MADD SMARCD1 UNC13C

6.77e-041951055DOID:1574 (implicated_via_orthology)
Diseasemultiple myeloma, monoclonal gammopathy

TOM1 DNAH11

1.11e-03141052EFO_0000203, EFO_0001378
Diseaseoral squamous cell carcinoma (is_marker_for)

ATP6V1C1 ERBB2 ATM

1.49e-03631053DOID:0050866 (is_marker_for)
DiseaseBenign neoplasm of stomach

ERBB2 ATM

1.65e-03171052C0153943
DiseaseNeoplasm of uncertain or unknown behavior of stomach

ERBB2 ATM

1.65e-03171052C0496905
DiseaseCarcinoma in situ of stomach

ERBB2 ATM

1.65e-03171052C0154060
Diseasenucleotide measurement

SYNE2 UNC13C ENPEP

2.27e-03731053EFO_0010513
Diseasejuvenile idiopathic arthritis

ATP6V1C1 ABCA13 MFSD6

2.36e-03741053EFO_0002609
DiseaseStomach Carcinoma

ERBB2 ATM

2.52e-03211052C0699791
Diseaselevel of Sphingomyelin (d40:2) in blood serum

NPFFR2 SYNE2

3.02e-03231052OBA_2045181
DiseaseImmunologic Deficiency Syndromes

NBAS ATM

3.02e-03231052C0021051
DiseasePseudoaphakia

TDRD7 ATM

3.29e-03241052C0524524
Diseasestomach carcinoma (is_marker_for)

ATP6V1C1 ERBB2

3.29e-03241052DOID:5517 (is_marker_for)
DiseaseLens Opacities

TDRD7 ATM

3.29e-03241052C1510497
Diseaselung squamous cell carcinoma (is_implicated_in)

E2F1 ATM

3.29e-03241052DOID:3907 (is_implicated_in)
Diseaseblood phosphate measurement

MFSD6 USP8 PARP9 GOLGB1

3.52e-031741054EFO_0010972

Protein segments in the cluster

PeptideGeneStartEntry
KKQDIENILHWNVTQ

ACO1

56

P21399
KKLLEVTNNGAVWNH

FAM200B

311

P0CF97
QIQLWHFILELLQKE

ERFL

41

A0A1W2PQ73
TILWKDIFHKNNQLA

ERBB2

166

P04626
VQIAWQIYRHQQKIK

FBRSL1

596

Q9HCM7
WTKAHNLLCQQKIQK

NT5C3B

106

Q969T7
KINKIKWLPQQNAAH

PPP2R2C

91

Q9Y2T4
WRILKSHVEKLDNQV

SSX2IP

346

Q9Y2D8
KLKSQTQHPWEKLLN

GVINP1

61

Q7Z2Y8
FEKTWLSLKVAHQQV

AP4B1

631

Q9Y6B7
ILVPVLSNKNNHKSW

DNAH11

166

Q96DT5
SIKAPQWTKKELHQQ

ABCA13

3941

Q86UQ4
QWTKKELHQQVNQTL

ABCA13

3946

Q86UQ4
LQEWVEHLQKQTKVT

ARHGEF7

566

Q14155
AKLILVNFHWQVSEI

ARIH2

91

O95376
LNLIWQLTDTKQLVH

CD276

281

Q5ZPR3
LKAVLQKQGIWSEIH

ASB14

511

A6NK59
KKLSQPITVQVWNHR

CAPN5

571

O15484
VKRLWHFLVKQEVLQ

DMXL2

2611

Q8TDJ6
KILSLQKHLEQLWSV

CCDC87

676

Q9NVE4
HLQRWKQLQEDLQSK

CCDC27

546

Q2M243
QEQWHVVSRKKQKII

NPFFR2

361

Q9Y5X5
SWQIPINHNDFKILK

PARP9

61

Q8IXQ6
KLKVLWLNHNTIKNI

LRRC9

121

Q6ZRR7
LLLLADHFWKKVQLQ

AOAH

536

P28039
FIASIELWNKHQEVK

MADD

1116

Q8WXG6
NAWIILSISAKQQKH

GPR162

31

Q16538
HQQDALWTEKLQVLK

GOLGA4

621

Q13439
VWQKSVHKLRKIAAQ

FAM182A

116

Q5T1J6
NLHKVIVVWNNIGEK

EXTL2

91

Q9UBQ6
KLVHLQKWDGQETTL

FABP3

91

P05413
NAKQIWIDKTVINDH

MORC3

46

Q14149
VKEWQKLIFLHPNNT

NRDE2

401

Q9H7Z3
QKKNHFQITIHIQVW

MYRFL

261

Q96LU7
MLKVNQTLKHLWLIQ

NOD1

891

Q9Y239
QTLKHLWLIQNQITA

NOD1

896

Q9Y239
FLEQQNKVLETKWHL

KRT78

131

Q8N1N4
NKVLETKWHLLQQQG

KRT78

136

Q8N1N4
WQQLVDDAKENLHKI

KNTC1

451

P50748
VKQKLLHWVSLLGQQ

NLRP5

661

P59047
KHLTKLRHWQQVLED

MED28

131

Q9H204
TVKNNIEWLKQHRNT

ENPEP

931

Q07075
KKLWHQLTLQVLDFV

PSMD13

31

Q9UNM6
WIEKHCVKINNDLLI

MFSD6

56

Q6ZSS7
LKDLILLIKHWHQQC

OAS2

196

P29728
KQINWHLVLASNGKL

NBAS

86

A2RRP1
LAISHQLIKEWVEKQ

NUDT13

331

Q86X67
HLLKAQAQVSEWKFL

KICS2

196

Q96MD2
LGWEVIKDHLQKSQN

ATM

391

Q13315
HALKLSEVQVKIWFQ

GBX1

296

Q14549
NDALHKKQLLNLWIS

GTPBP10

351

A4D1E9
AILKWISHDPQNRKQ

KLHL10

206

Q6JEL2
GIQLIAKKSKNHIQW

E2F1

176

Q01094
TLKIIKHLQENWADI

AXDND1

541

Q5T1B0
KLQWQTTLGHAVLKA

CUL4A

566

Q13619
WISILNSNEHLLKEK

CEP85

326

Q6P2H3
ALWEKNTHLEAQLQK

CEP250

656

Q9BV73
KKCNLHLVDIWNVIE

DTNA

46

Q9Y4J8
QQVLKKITFWAAANH

KLHDC1

371

Q8N7A1
NSHIAKLQELWKTPQ

FAM216A

71

Q8WUB2
KLQELWKTPQNQTIH

FAM216A

76

Q8WUB2
LRIVFVHNKAVIWQK

PMS1

186

P54277
QKLQRCHVQNTIIKW

CARD16

126

Q5EG05
NVTWKIKLRNAIHLS

TAS2R19

161

P59542
NVTWKIKLRNAIHLS

TAS2R33

161

P0DSN6
NVTWKIKLRNAIHLS

TAS2R36

161

P0DTE0
HKTLVIKKSVNPQWN

SYTL5

626

Q8TDW5
LLKRHLQEKQNNQIW

TAF5

316

Q15542
ILVKKWIHLSVQVHQ

USH2A

206

O75445
LVVVPKLNHNDWIKQ

ATP6V1C1

186

P21283
LQWAKHLGNAVKVTI

TRMT1L

291

Q7Z2T5
NSWQVHLVLLPIKKQ

SYT14

296

Q8NB59
VIKIHWQEKKSNTIL

TRGC1

41

P0CF51
IIKIHWQEKKSNTIL

TRGC2

41

P03986
IQALWQYIKTHKLQD

SMARCD1

316

Q96GM5
INNLKKQWETLEPLH

SYNE2

2706

Q8WXH0
ELQLGLKEKQWQLSH

SYNE3

141

Q6ZMZ3
LKEKQWQLSHAQVLL

SYNE3

146

Q6ZMZ3
KNNALNQVVLWDKIV

SPCS3

96

P61009
HVEWVNALILKNKLK

ST8SIA4

236

Q92187
IKEILNKHNNGIWIS

TDRD7

241

Q8NHU6
KILLDEQAQWKHYLV

ICAM2

66

P13598
QQLWKQNPKDIHTLA

SRP72

471

O76094
ALQKWLQLTHEVEVQ

STIM1

346

Q13586
QEYQEWVIKLHQDLK

C12orf4

221

Q9NQ89
WILVTKEQHRQLKSL

SNX17

236

Q15036
LELIIKHKNQFLDIW

RNF213

1106

Q63HN8
LWIKHLVIKDSKLNN

SMOC1

201

Q9H4F8
SQEQTFQLLKLWKHQ

TNFRSF11B

246

O00300
NRVWTELIHSKKQVL

WDFY3

2201

Q8IZQ1
HKVTVKVIAINDLNW

UNC13C

2061

Q8NB66
NLQILVHVTKEGVWK

RLF

171

Q13129
LAVKQVLANKSHLWV

STEAP3

336

Q658P3
KEHIQKLVKTGENNW

SESN3

171

P58005
TIVHDKVLNLIQSWA

TOM1

111

O60784
QKPDNKLHQQVLWRL

PRND

121

Q9UKY0
AIEKKIHASQQRWQQ

PHF11

281

Q9UIL8
KLWNLIKDQIADVHL

USP41

146

Q3LFD5
LLQQVHGKPWKTQIL

TRMT12

406

Q53H54
LQAKNQEEKRLWIHC

PLEKHG2

391

Q9H7P9
KLWNLIKDQITDVHL

USP18

146

Q9UMW8
VQAKSQQDKRLWVLH

PLEKHG1

396

Q9ULL1
IQIWQKTVKEAHLTK

TBCCD1

501

Q9NVR7
LAILPKELQAWVQKH

ZNF396

101

Q96N95
FIITKKEEVQQLWHD

TSPAN19

106

P0C672
WQKHKQLNESIIVAL

USP8

911

P40818
WNLQTKEIVQKLQGH

WDR5

286

P61964
ALQEKVEIKQLNHFW

XRCC5

661

P13010
LNSEIHQVTKIWRKV

TBC1D2

471

Q9BYX2
IENKQDWIKHIREVI

TRIO

1576

O75962
WNVKLLKVDQDSALH

UBE2Q1

286

Q7Z7E8
KINISRLEHDKQIWE

GOLGB1

2251

Q14789
AKQVLQHPWVTQKDK

RPS6KA1

666

Q15418
DFWKAVIQVRQKTLH

NMD3

151

Q96D46